Evidence map›Paper›PMID 38750392›Full record

ArticleNeurocritical care2024

Early Celecoxib Use in Spontaneous Intracerebral Hemorrhage is Associated with Reduced Mortality.

Bao Y Sciscent, David R Hallan, Debarati Bhanja, Jacob Staub, Derek Crossman, Elias B Rizk, J Christopher Zacko, Haejoe Park, Sprague W Hazard

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Neurocritical care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bao Y SciscentDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
David R HallanDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. dhallan@pennstatehealth.psu.edu.
Debarati BhanjaDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Jacob StaubDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Derek CrossmanDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Elias B RizkDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
J Christopher ZackoDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Haejoe ParkDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
Sprague W HazardDepartment of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
NCATS NIH HHS UL1 TR002014
6 · The paper itself

Abstract

backgroundHemorrhagic strokes constitute 10-15% of all strokes and have the worst mortality and morbidity of all subtypes. Mortality and morbidity of spontaneous intracerebral hemorrhage (sICH) are often secondary to the effects of inflammation, brain edema, and swelling. Studies have shown that celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, reduces perihematomal edema formation and inflammation. This study aimed to examine the impact of celecoxib on sICH outcomes.

methodsTriNetX, a multi-institutional research database, was retrospectively queried to identify patients with sICH. Outcomes in patients who received celecoxib within 5 days (cohort 1) were analyzed and compared to those in patients who did not receive celecoxib (cohort 2). The primary end point was mortality within 1 year of sICH. Secondary end points included ventilator dependence, tracheostomy, percutaneous endoscopic gastrostomy tube placement, craniotomy, deep venous thrombosis, pulmonary embolism, ischemic stroke, transient ischemia attack, myocardial infarction, and seizures. Further analysis was performed to assess these outcomes for patients treated with ibuprofen, a nonselective COX inhibitor.

resultsAfter propensity score matching, 833 patients were identified in each cohort based on celecoxib use. Mortality at 1 year was significantly reduced in patients with sICH receiving celecoxib compared to those who did not (13.33% vs. 17.77%; p = 0.0124). Risks of ventilator dependence, tracheostomy, percutaneous endoscopic gastrostomy tube placement, craniotomy, deep venous thrombosis, pulmonary embolism, ischemic stroke, transient ischemia attack, myocardial infarction, and seizures were not significantly increased in patients who received celecoxib within 5 days of sICH compared to those who did not receive celecoxib. There was no significant difference in mortality between patients based on ibuprofen administration.

conclusionsThere exists a growing interest in using COX-2 as a potential target strategy for neuroprotection in patients with sICH, with some evidence of a mortality benefit in small cohort studies. This study shows that early celecoxib use is associated with decreased mortality in patients with sICH.

Indexed as

CelecoxibCerebral HemorrhageCyclooxygenase 2 InhibitorsAgedAged, 80 and overFemaleHemorrhagic StrokeHumansIbuprofenMaleMiddle AgedRetrospective StudiesCelecoxibCyclooxygenase 2 InhibitorsIbuprofenCelecoxibMortality rateNeurosurgeryOutcomesSpontaneous intracerebral hemorrhageSurvival

Identifiers

PMID38750392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.